Capecitabine - Roche

Drug Profile

Capecitabine - Roche

Alternative Names: Capecitabine RDT; R340; RG 340; RO 091978; Ro09-1978; Xeloda; Xelox

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Alliance for Clinical Trials in Oncology; Beth Israel Deaconess Medical Center; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Ludwig-Maximilians-University; Roche; Samsung Medical Center; Sanofi; University of Chicago
  • Class Antineoplastics; Carbamates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Colorectal cancer; Gastric cancer
  • Registered Rectal cancer
  • Phase II Glioma; Intestinal cancer; Oesophageal cancer; Pancreatic cancer
  • No development reported Cervical cancer; Lung cancer; Nasopharyngeal cancer
  • Discontinued Biliary cancer

Most Recent Events

  • 01 Sep 2017 Yakult Honsha initiates enrolment in a phase II trial in Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease) in Japan (IV) (UMIN000028749)
  • 01 Apr 2017 Roche terminates a phase III trial in Colorectal cancer (First-line therapy, Metastatic disease) in South Korea (PO) (NCT02060669)
  • 10 Jan 2017 Roche completes a phase III trial in Breast cancer (Combination therapy, Early-stage disease) in Portugal, Italy, United Kingdom, Germany, Slovenia, Spain, Belgium, Netherlands (PO) (NCT00433589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top